Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials-Reference-Cited by-同舟云学术

Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

Published:2020-03-17 Issue:1 Volume:35 Page:169-176
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Al-Sawaf O.^ORCID,Robrecht S.,Bahlo J.,Fink A. M.,Cramer P.,v Tresckow J.,Lange E.,Kiehl M.,Dreyling M.,Ritgen M.,Dürig J.,Tausch E.,Schneider C.,Stilgenbauer S.,Wendtner C. M.,Fischer K.,Goede ,Hallek M.,Eichhorst B.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0797-x.pdf

Reference48 articles.

1. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761–72.

2. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391–401.

3. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification tumours 2008. 2008;22008:439.

4. Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012;156:50–66.

5. Brecher M, Banks PM. Hodgkin’s disease variant of Richter’s syndrome. Report of eight cases. Am J Clin Pathol. 1990;93:333–9.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02

2. Treatment of Richter transformation—immunotherapy to the rescue?;The Lancet Oncology;2024-09

3. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

4. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study;The Lancet Haematology;2024-09

5. SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07